These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18691131)

  • 21. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease.
    Grychowska K; Satała G; Kos T; Partyka A; Colacino E; Chaumont-Dubel S; Bantreil X; Wesołowska A; Pawłowski M; Martinez J; Marin P; Subra G; Bojarski AJ; Lamaty F; Popik P; Zajdel P
    ACS Chem Neurosci; 2016 Jul; 7(7):972-83. PubMed ID: 27100049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models.
    Ivachtchenko AV; Ivanenkov YA; Veselov MS; Okun IM
    Curr Alzheimer Res; 2017; 14(3):268-294. PubMed ID: 27829340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.
    Upton N; Chuang TT; Hunter AJ; Virley DJ
    Neurotherapeutics; 2008 Jul; 5(3):458-69. PubMed ID: 18625457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease.
    Schechter LE; Dawson LA; Harder JA
    Curr Pharm Des; 2002; 8(2):139-45. PubMed ID: 11812255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
    Ivachtchenko AV; Ivanenkov YA; Skorenko AV
    Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idalopirdine as a treatment for Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2015; 24(7):981-7. PubMed ID: 26022777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease.
    Hirano K; Piers TM; Searle KL; Miller ND; Rutter AR; Chapman PF
    Life Sci; 2009 Apr; 84(15-16):558-62. PubMed ID: 19302808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
    de Bruin NM; Prickaerts J; van Loevezijn A; Venhorst J; de Groote L; Houba P; Reneerkens O; Akkerman S; Kruse CG
    Neurobiol Learn Mem; 2011 Sep; 96(2):392-402. PubMed ID: 21757018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease.
    Garcia-Alloza M; Hirst WD; Chen CP; Lasheras B; Francis PT; Ramírez MJ
    Neuropsychopharmacology; 2004 Feb; 29(2):410-6. PubMed ID: 14571255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia.
    Nikiforuk A
    Rev Neurosci; 2014; 25(3):367-82. PubMed ID: 24501158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arylpiperazine derivatives acting at 5-HT(1A) receptors.
    López-Rodríguez ML; Ayala D; Benhamú B; Morcillo MJ; Viso A
    Curr Med Chem; 2002 Feb; 9(4):443-69. PubMed ID: 11945120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon.
    Okun I; Tkachenko SE; Khvat A; Mitkin O; Kazey V; Ivachtchenko AV
    Curr Alzheimer Res; 2010 Mar; 7(2):97-112. PubMed ID: 19939222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.
    Liu KG; Robichaud AJ; Greenfield AA; Lo JR; Grosanu C; Mattes JF; Cai Y; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Comery TA
    Bioorg Med Chem; 2011 Jan; 19(1):650-62. PubMed ID: 21093272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin 6 receptor controls Alzheimer's disease and depression.
    Yun HM; Park KR; Kim EC; Kim S; Hong JT
    Oncotarget; 2015 Sep; 6(29):26716-28. PubMed ID: 26449188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Potential of 5-HT6 Receptor Agonists.
    Karila D; Freret T; Bouet V; Boulouard M; Dallemagne P; Rochais C
    J Med Chem; 2015 Oct; 58(20):7901-12. PubMed ID: 26099069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT6 receptors: a novel target for cognitive enhancement.
    Mitchell ES; Neumaier JF
    Pharmacol Ther; 2005 Dec; 108(3):320-33. PubMed ID: 16005519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-hydroxytryptamine (5-HT) receptor ligands.
    Kitson SL
    Curr Pharm Des; 2007; 13(25):2621-37. PubMed ID: 17897004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
    Gravius A; Laszy J; Pietraszek M; Sághy K; Nagel J; Chambon C; Wegener N; Valastro B; Danysz W; Gyertyán I
    Behav Pharmacol; 2011 Apr; 22(2):122-35. PubMed ID: 21301322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.
    Johnson CN; Ahmed M; Miller ND
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):642-54. PubMed ID: 18729016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.